OncoMatch/Clinical Trials/NCT06268665
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
Is NCT06268665 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tart Cherry Juice for breast cancer.
Treatment: Tart Cherry Juice — This is a single institution phase II randomized study evaluating the potential benefits of a supplement, tart cherry juice at high- versus low-doses, to prevent taxane induced peripheral neuropathy in breast and ovarian cancer patients undergoing paclitaxel chemotherapy. Eligible participants enrolled onto the study will be block randomized in a 1:1 allocation to either the tart cherry juice high-dose group (Arm 1) or the tart cherry juice low-dose group (Arm 2).
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Ovarian Cancer
Tumor Agnostic
Disease stage
Required: Stage I, II, III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: taxane
Have received any prior therapy with taxanes
Cannot have received: vinca alkaloid
Have received any prior therapy with ... vinca alkaloids
Cannot have received: antimicrotubule agent (eribulin, ixabepilone)
Have received any prior therapy with ... eribulin, ixabepilone
Cannot have received: platinum-based chemotherapy
Have received any prior therapy with ... platinum
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California Davis Comprehensive Cancer Center · Sacramento, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify